neoag
Neoantigen × AI
Daily research signal
FIELD MAP / MODALITY

DNA vaccines

Plasmid-DNA vaccines encoding neoantigens, typically delivered by electroporation — the platform behind Geneos' and several academic programs.

Topic11 items2026-05-30 – 2026-07-15
Modalities
Peptide vaccines64TCR & T-cell receptor34mRNA vaccines31Dendritic-cell vaccines25Shared & off-the-shelf16DNA vaccines11Lipid nanoparticles5Viral-vector vaccines4Oncolytic viruses1
01
AI / Methods

Intramuscular plasmid DNA electroporation sequesters neoantigen-specific CD8<sup>+</sup> T cells in treated muscle and limits tumor infiltration.

A study on plasmid DNA electroporation for neoantigen vaccines reveals that the technique sequesters activated CD8+ T cells in the treated muscle tissue rather than promoting tumor infiltration. While the method induces strong local immune gene activation, flow cytometry showed neoantigen-specific T cells accumulating at the vaccination site instead of the tumor. This suggests that electroporation-induced tissue remodeling may limit therapeutic efficacy by trapping effector cells away from the cancer.

europepmc · brief 2026-07-15 · published 2026-05-28
02
Clinical

GT-20 Trial: Personalized Neoantigen Vaccines for Glioblastoma - Oncodaily

GT Biopharma’s GNOS-PV01, a personalized DNA vaccine targeting patient-specific mutations in MGMT-unmethylated glioblastoma, is being evaluated in a Phase 1 study published in Nature Cancer. The trial utilizes multi-regional tumor sampling to address high heterogeneity, aiming to induce immune responses against dozens of neoantigens rather than single targets. This approach addresses the lack of efficacy seen with prior immunotherapies in this aggressive cancer subtype.

GlioblastomaGeneos Therapeutics
news · brief 2026-07-01 · published 2026-06-18
05
Clinical

Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Washington University School of Medicine is conducting an active, non-recruiting Phase 1 study of a personalized DNA neoantigen vaccine in patients with newly diagnosed, unmethylated glioblastoma. The open-label trial focuses on assessing the safety, feasibility, and immunogenicity of the approach in this aggressive brain cancer subtype.

Glioblastoma
clinicaltrials · brief 2026-06-08 · published 2026-05-07
07
Clinical

Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Washington University School of Medicine is running a Phase I study of a personalized neoantigen-based DNA vaccine combined with retifanlimab (PD-1 blockade) in newly diagnosed, unmethylated glioblastoma. The trial assesses safety and immunogenicity, targeting a population with limited therapeutic options.

Glioblastoma
clinicaltrials · brief 2026-06-02 · published 2026-05-04
10
Clinical

Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors

Washington University School of Medicine is recruiting for a Phase 1 study assessing the safety and feasibility of a personalized DNA vaccine in pediatric patients with recurrent or treatment-resistant central nervous system tumors. This trial targets a population with limited therapeutic options, focusing on the technical feasibility of delivering personalized DNA constructs in this demographic.

clinicaltrials · brief 2026-05-30 · published 2026-05-07
11
Clinical

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

Geneos Therapeutics is conducting a Phase I/IIa single-arm study of GNOS-PV02, a personalized neoantigen DNA vaccine, combined with plasmid-encoded IL-12 (INO-9012) and pembrolizumab in advanced hepatocellular carcinoma (HCC). The trial is currently active but not recruiting, focusing on the combination of DNA-based immunization with immune checkpoint inhibition.

Liver cancer (HCC)Geneos Therapeutics
clinicaltrials · brief 2026-05-30 · published 2026-04-22
Where nextAll topicsToday’s briefTrials tracker